Clinical trials: DLBCL
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL.
- Trial name
- NCT05664217
- Testing
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nektar Therapeutics
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma
DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- NCT04792489
- Testing
- zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine
- Where
- 32 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- Miltenyi Biomedicine GmbH
Diffuse Large B-Cell Lymphoma, Drug Toxicity
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subset of non-Hodgkin's lymphoma (NHL). Central nervous system (CNS) involvement in patients with NHL is a serious complication.
- Trial name
- NCT05022797
- Testing
- Glucarpidase 1000 UNT [Voraxaze]
- Where
- 2 sites in Spain
- Volunteers
- 3 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Diffuse Large B-cell Lymphoma
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the treatment of localized CD20 (+) diffuse large B-cell lymphoma
- Trial name
- ASPIRE (NCT02054559)
- Testing
- R-CHOP, Radiotherapy
- Where
- South Korea
- Sponsor
- Asan Medical Center
Lymphoma, Non-Hodgkin's, Adult
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.
- Trial name
- NCT05078840
- Testing
- Evaluation of first line treatment in patients with stage I and II LBCL
- Where
- 7 sites in Argentina
- Volunteers
- 75 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab
EBV-Positive DLBCL, Nos
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an…
- Trial name
- NCT04181489
- Testing
- Sintilimab, Rituximab, Cyclophosphamide
- Where
- 11 sites in China
- Volunteers
- 55 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University